Topic: cancer-killing virus
The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
New data from Amgen suggest adding an oncolytic virus could add even more punch to the treatment of melanoma.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
Two research teams are testing companion therapies that might boost the effectiveness of immune-boosting checkpoint inhibitors in treating cancer.
Researchers are investigating a potentially useful role for Zika virus: treating glioblastoma.
Oncolytic viruses, which have had limited success in human trials, may get a boost from a protein-inhibiting agent.
Viralytics just reported impressive data for its virus-based cancer therapy that could bring commercial partners out of the woodwork.
Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million. As part of the deal, the pharma gains the right to buy the biotech.
Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme.